论文部分内容阅读
目的探讨复方鳖甲软肝片联合恩替卡韦在乙肝后肝硬化中的临床治疗效果。方法选择攀枝花市第四人民医院2013年1月至2014年1月收治的94例乙肝肝硬化患者,按照患者自愿原则,将患者分为对照组与观察组,每组47例。对照组患者口服恩替卡韦片,观察组患者口服恩替卡韦片配合复方鳖甲软肝片,4周为一个疗程,连续治疗6个疗程。统计分析治疗后患者肝功能指标(ALT、AST、TBi L)的变化,观察两组临床治疗效果。结果观察组与对照组临床治疗效果分别为91.49%(43/47)、70.21%(33/47),差异有统计学意义(P<0.05);与治疗前比较,两组肝功能指标差异均有统计学意义(P<0.01),治疗后观察组ALT、AST与对照组比较均变化明显,差异均有统计学意义(P均<0.01),TBi L值与对照组比较也有变化(P<0.05)。结论复方鳖甲软肝片联合恩替卡韦在治疗乙肝肝硬化方面具有明显的治疗效果,能有效改善患者肝功能各项指标,延缓肝硬化进程,是值得应用的口服治疗方法。
Objective To investigate the clinical effect of Fufang Biejia Ruangan Pian combined with entecavir in post-hepatitis B cirrhosis. Methods Ninety-four patients with hepatitis B cirrhosis admitted from January 2013 to January 2014 in Panzhihua Fourth People’s Hospital were enrolled. Patients were divided into control group and observation group according to the voluntary principle of patients, with 47 cases in each group. Patients in the control group were given oral entecavir tablets. Patients in the observation group were given oral entecavir tablets with compound Biejia Ruangan tablets for 4 weeks for one course of treatment for 6 courses. Statistical analysis of liver function indicators (ALT, AST, TBi L) changes after treatment, the clinical efficacy of the two groups were observed. Results The clinical effects of the observation group and the control group were 91.49% (43/47) and 70.21% (33/47), respectively, with statistical significance (P <0.05). Compared with those before treatment, the differences of the liver function indexes (P <0.01). After treatment, ALT and AST in the observation group changed significantly compared with the control group, the differences were statistically significant (P <0.01), TBi L value also had changes compared with the control group (P < 0.05). Conclusion Fufang Biejia Ruangan Pian combined with entecavir has significant curative effect in the treatment of hepatitis B cirrhosis. It can effectively improve various indexes of liver function and delay the process of liver cirrhosis. It is worthwhile to use oral treatment.